Glooko is a company that focuses on improving health outcomes for individuals with diabetes and related chronic conditions, operating within the healthcare and digital health sectors. The company offers a connected care platform that provides personalized care, drives patient engagement and adherence through digital therapeutics, and accelerates the speed of clinical trials. Glooko primarily serves the healthcare industry, with a particular focus on providers and patients dealing with chronic conditions. Glooko was formerly known as OTA Health Inc.. It was founded in 2010 and is based in Palo Alto, California.
Glooko's Products & Differentiators
High security RPM platform/patient app for managing chronic conditions fully integrated into health systems' EMR systems and payors population health systems
Research containing Glooko
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Glooko in 7 CB Insights research briefs, most recently on Jan 27, 2023.
Expert Collections containing Glooko
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Glooko is included in 5 Expert Collections, including Digital Health 150.
Digital Health 150
The most promising digital health startups transforming the healthcare industry
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Glooko has filed 4 patents.
Diabetes, Insulin therapies, Blood tests, Implants (medicine), Syndromes
Diabetes, Insulin therapies, Blood tests, Implants (medicine), Syndromes
Latest Glooko News
Oct 25, 2023
News provided by Share this article Share toX PALO ALTO, Calif., Oct. 25, 2023 /PRNewswire/ -- Glooko, Inc., a global leader in chronic condition management, specializing in connected care and remote patient monitoring for diabetes and other related diseases, today announced the appointment of Enrique Conterno to its Board of Directors. Mr. Conterno is a well-known executive in the pharmaceutical industry with deep expertise in the diabetes field. He joins the board of Glooko having served most recently as the Chief Executive Officer and a member of the Board at FibroGen, Inc. Before FibroGen, Mr. Conterno was Senior Vice President for Eli Lilly and Company, serving as President of Lilly USA from January 2017, and President of Lilly Diabetes from 2009, until his retirement from Lilly in December 2019. Prior to 2009, Mr. Conterno served in various other roles for Eli Lilly and Company, including President, U.S. Operations, Vice President for the U.S. Neuroscience Business Unit, President and General Manager, Mexico, and Executive Marketing Director, Intercontinental Operations and Japan. Mr. Conterno earned a Bachelor of Science degree in Mechanical Engineering from Case Western Reserve University and a Master of Business Administration from Duke University. He is a member of the Board of Governors of the American Red Cross. "We are extremely pleased to welcome Enrique to our Board. His deep knowledge of the diabetes space and his leadership of the diabetes enterprise at Lilly will be invaluable to Glooko as we grow our connected care business in diabetes and related chronic conditions as well as our digital life sciences practice," said Russ Johannesson, CEO of Glooko. "In addition, his broad experience from his operational, marketing and growth leadership roles will help to guide our strategic vision of becoming the go-to platform for chronic care management." Mr. Conterno has deep familiarity with the global healthcare ecosystem and has overseen multiple, important major product launches in the diabetes space. His three decades of leadership and proven track record of growing revenues and businesses will further enhance Glooko's already significant global positioning in the digital life sciences marketplace. "I am delighted to join the board of Glooko during this pivotal and important time in the company's history and look forward to working with the team to grow the diabetes franchise as well as penetrate the rapidly growing adjacent areas, including obesity and cardiometabolic disease," said Mr. Conterno. "Glooko brings innovative digital health solutions to patients, providers, and clinical and pharmaceutical companies around the world. I am excited to leverage my insights to help Glooko to reach its full potential." About Glooko Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com . Media Inquiries:
Glooko Frequently Asked Questions (FAQ)
When was Glooko founded?
Glooko was founded in 2010.
Where is Glooko's headquarters?
Glooko's headquarters is located at 411 High St., Palo Alto.
What is Glooko's latest funding round?
Glooko's latest funding round is Series D.
How much did Glooko raise?
Glooko raised a total of $102.5M.
Who are the investors of Glooko?
Investors of Glooko include Canaan Partners, Georgian, Mayo Clinic Ventures, Insulet, Health Catalyst Capital Management and 20 more.
Who are Glooko's competitors?
Competitors of Glooko include enhance-d, Doctomatic, TidePool, Rimidi, BeatO and 7 more.
What products does Glooko offer?
Glooko's products include Glooko Enterprise and 2 more.
Who are Glooko's customers?
Customers of Glooko include University of Michigan and Sharp Rees Steely.
Compare Glooko to Competitors
One Drop operates as a diabetes management platform. It allows users to track their glucose levels using a variety of devices, including blood glucose meters, continuous glucose monitors (CGMs), and insulin pumps. It also offers a mobile application that provides personalized coaching to help users achieve their health goals. The company was founded in 2014 and is based in New York, New York.
WellDoc is a company that focuses on the healthcare technology sector, specifically in the domain of chronic care management. The company offers an AI-driven digital coaching platform that aids in the self-management of various chronic conditions such as diabetes, hypertension, heart failure, and obesity. The platform also provides data-driven insights to support care team interventions and decision making, and promotes general wellness and education. WellDoc primarily serves health plans, health systems, employers, and partners in the healthcare industry. It was founded in 2005 and is based in Baltimore, Maryland.
BeatO develops diabetes care and management application to manage and prevent health problems. It offers health monitoring, health insights, daily coaching from experts, health plans, nutrition support, lab tests, and pharmacy. The company offers smartphone glucometers and connected monitoring devices helping users to monitor and get guidance for blood sugar, blood pressure, and other health vitals. The company was founded in 2015 and is based in New Delhi, India.
Emperra is a research and innovation-oriented medical technology company with a focus on Health-IT and tele-diabetology. The company offers a comprehensive, state-of-the-art, and AI-enabled diabetes management solution that aids individuals with diabetes in managing their metabolic conditions and assists healthcare professionals in their daily practice. The primary sector that Emperra serves is the healthcare industry, specifically in the area of diabetes management. It was founded in 2008 and is based in Potsdam, Germany.
Curo Healthcare Technologies runs Life In Control, a digital diabetes management program. The Life in Control app, which is available both in Android and iOS platforms, is designed to connect doctors and patients to help patients better manage their glycemic status in collaboration with their doctors. It also analyzes patients' historical data to predict secondary complications aimed at preventing diabetes and promoting wellness.
Omada Health operates as a digital behavioral medicine company. The company helps to protect patients from chronic conditions like heart disease and type two diabetes. It offers behavioral counseling by using insights about social networking, gaming, and behavioral sciences. It primarily serves sectors such as employers, health plans, benefit consultants, and health systems & providers. Omada Health serves the It was founded in 2011 and is based in San Francisco, California.